Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates

被引：0

作者：

Von Hoff, Daniel D.

Ervin, Thomas J.

Arena, Francis P.

Chiorean, E. Gabriela

Infante, Jeffrey R.

Moore, Malcolm J.

Seay, Thomas E.

Tjulandin, Sergei

Ma, Wen Wee

Saleh, Mansoor N.

Harris, Marion

Reni, Michele

Ramanathan, Ramesh K.

Tabernero, Josep

Hidalgo, Manuel

Van Cutsem, Eric

Goldstein, David

Wei, Xinyu

Iglesias, Jose Luis

Renschler, Markus Frederic

机构：

[1] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA

[2] Florida Canc Specialists, Englewood, FL USA

[3] Arena Oncol Associates, Lake Success, NY USA

[4] Univ Washington, Seattle, WA 98195 USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Tennessee Oncol, Nashville, TN USA

[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[8] Atlanta Canc Care, Atlanta, GA USA

[9] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia

[10] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[11] Georgia Canc Specialists PC, Atlanta, GA USA

[12] Southern Hlth, East Bentleigh, Vic, Australia

[13] Univ Milan, Osped San Raffaele, Ist Ricovero & Cura Carattere Sci, I-20127 Milan, Italy

[14] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr, Scottsdale, AZ USA

[15] Vall dHebron Univ Hosp, Barcelona, Spain

[16] Ctr Integral Oncol Clara Campal, Madrid, Spain

[17] Katholieke Univ Leuven Hosp, Louvain, Belgium

[18] Prince Wales Hosp, Sydney, NSW, Australia

[19] Celgene Corp, Summit, NJ USA

[20] Bionomics Ltd, Thebarton, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4005

引用

页数：1

共 50 条

[31] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
Grierson, Patrick M.
Tan, Benjamin
Pedersen, Katrina S.
Park, Haeseong
Suresh, Rama
Amin, Manik A.
Trikalinos, Nikolaos A.
Knoerzer, Deborah
Kreider, Brent
Reddy, Anupama
Liu, Jingxia
Der, Channing J.
Wang-Gillam, Andrea
Lim, Kian-Huat
ONCOLOGIST, 2023, 28 (02): : E115 - E123
[32] Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
Reni, M.
Zanon, S.
Pircher, C.
Chiaravalli, M.
Macchini, M.
Peretti, U.
Mazza, E.
Balzano, G.
Passoni, P.
Nicoletti, R.
Arcidiacono, P. G.
Pepe, G.
Doglioni, C.
Romi, S.
Ceraulo, D.
Falconi, M.
Gianni, L.
ANNALS OF ONCOLOGY, 2017, 28
[33] Adjuvant nab-Paclitaxel plus Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open -Label, Phase III Trial
Tempero, Margaret A.
Pelzer, Uwe
O'Reilly, Eileen M.
Winter, Jordan
Oh, Do-Youn
Li, Chung-Pin
Tortora, Giampaolo
Chang, Heung-Moon
Lopez, Charles D.
Bekaii-Saab, Tanios
Ko, Andrew H.
Santoro, Armando
Park, Joon Oh
Noel, Marcus S.
Frassineti, Giovanni Luca
Shan, Yan-Shen
Dean, Andrew
Riess, Hanno
Van Cutsem, Eric
Berlin, Jordan
Philip, Philip
Moore, Malcolm
Goldstein, David
Tabernero, Josep
Li, Mingyu
Ferrara, Stefano
Le Bruchec, Yvan
Zhang, George
Lu, Brian
Biankin, Andrew V.
Reni, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 2007 - +
[34] Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
Bekaii-Saab, Tanios
Okusaka, Takuji
Goldstein, David
Oh, Do-Youn
Ueno, Makoto
Ioka, Tatsuya
Fang, Weijia
Anderson, Eric C.
Noel, Marcus S.
Reni, Michele
Choi, Hye Jin
Goldberg, Jonathan S.
Oh, Sang Cheul
Li, Chung-Pin
Tabernero, Josep
Li, Jian
Foos, Emma
Oh, Cindy
Van Cutsem, Eric
ECLINICALMEDICINE, 2023, 58
[35] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
Yu, X.
Shen, L.
Hao, J.
Wang, L.
Pan, H.
Han, G.
Xu, J.
Zhang, Y.
Yang, S.
Ying, J.
Li, M.
Begic, D.
Lu, B.
Xu, R.
ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
[36] SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial (vol 21, pg 4811, 2015)
Hidalgo, M.
Plaza, C.
Musteanu, M.
Illei, P.
Brachmann, C. B.
Heise, C.
CLINICAL CANCER RESEARCH, 2016, 22 (24) : 6302 - 6302
[37] Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Moore, Malcolm J.
Teixeira, Luis
Siena, Salvatore
Tabernero, Josep
Goldstein, David
Wei, Xinyu
Lu, Brian
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[38] Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
O'Reilly, Eileen M.
Barone, Diletta
Mahalingam, Devalingam
Bekaii-Saab, Tanios
Shao, Spencer H.
Wolf, Julie
Rosano, Molly
Krause, Silva
Richards, Donald A.
Yu, Kenneth H.
Roach, James M.
Flaherty, Keith T.
Ryan, David P.
EUROPEAN JOURNAL OF CANCER, 2020, 132 : 112 - 121
[39] Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, 6 capecitabine, cisplatin ( paxg regimen) in metastatic pancreatic adenocarcinoma
Zanon, S.
Pircher, C.
Chiaravalle, M.
Macchini, M.
Peretti, U.
Balzano, G.
Passoni, P.
Nicoletti, R.
Arcidiacono, P. G.
Pepe, G.
Doglioni, C.
Romi, S.
Gritti, E.
Falconi, M.
Gianni, L.
Reni, M.
ANNALS OF ONCOLOGY, 2017, 28 : 44 - 45
[40] Gemcitabine plus Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study
Zaibet, Simon
Hautefeuille, Vincent
Auclin, Edouard
Lievre, Astrid
Tougeron, David
Sarabi, Mathieu
Gilabert, Marine
Wasselin, Julie
Edeline, Julien
Artru, Pascal
Bechade, Dominique
Morin, Clemence
Ducoulombier, Agnes
Taieb, Julien
Pernot, Simon
BRITISH JOURNAL OF CANCER, 2022, 126 (10) : 1394 - 1400

← 1 2 3 4 5 →